CaMKII in myocardial hypertrophy and heart failure

Mark E. Anderson, Joan Heller Brown, Donald M Bers

Research output: Contribution to journalArticle

247 Citations (Scopus)

Abstract

Many signals have risen and fallen in the tide of investigation into mechanisms of myocardial hypertrophy and heart failure (HF). In our opinion, the multifunctional Ca and calmodulin-dependent protein kinase II (CaMKII) has emerged as a molecule to watch, in part because a solid body of accumulated data essentially satisfy Koch's postulates, showing that the CaMKII pathway is a core mechanism for promoting myocardial hypertrophy and heart failure. Multiple groups have now confirmed the following: (1) that CaMKII activity is increased in hypertrophied and failing myocardium from animal models and patients; (2) CaMKII overexpression causes myocardial hypertrophy and HF and (3) CaMKII inhibition (by drugs, inhibitory peptides and gene deletion) improves myocardial hypertrophy and HF. Patients with myocardial disease die in equal proportion from HF and arrhythmias, and a major therapeutic obstacle is that drugs designed to enhance myocardial contraction promote arrhythmias. In contrast, inhibiting the CaMKII pathway appears to reduce arrhythmias and improve myocardial responses to pathological stimuli. This brief paper will introduce the molecular physiology of CaMKII and discuss the impact of CaMKII on ion channels, Ca handling proteins and transcription in myocardium. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

Original languageEnglish (US)
Pages (from-to)468-473
Number of pages6
JournalJournal of Molecular and Cellular Cardiology
Volume51
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Calcium-Calmodulin-Dependent Protein Kinase Type 2
Hypertrophy
Heart Failure
Cardiac Arrhythmias
Myocardium
Myocardial Contraction
Gene Deletion
Cardiomyopathies
Ion Channels
Pharmaceutical Preparations
Animal Models

Keywords

  • Arrhythmias
  • Calmodulin kinase II
  • Cell signaling
  • Heart failure
  • Hypertrophy
  • Oxidation

ASJC Scopus subject areas

  • Molecular Biology
  • Cardiology and Cardiovascular Medicine

Cite this

CaMKII in myocardial hypertrophy and heart failure. / Anderson, Mark E.; Brown, Joan Heller; Bers, Donald M.

In: Journal of Molecular and Cellular Cardiology, Vol. 51, No. 4, 10.2011, p. 468-473.

Research output: Contribution to journalArticle

Anderson, Mark E. ; Brown, Joan Heller ; Bers, Donald M. / CaMKII in myocardial hypertrophy and heart failure. In: Journal of Molecular and Cellular Cardiology. 2011 ; Vol. 51, No. 4. pp. 468-473.
@article{14569a48ac924dc18aadaa6a7235d2ed,
title = "CaMKII in myocardial hypertrophy and heart failure",
abstract = "Many signals have risen and fallen in the tide of investigation into mechanisms of myocardial hypertrophy and heart failure (HF). In our opinion, the multifunctional Ca and calmodulin-dependent protein kinase II (CaMKII) has emerged as a molecule to watch, in part because a solid body of accumulated data essentially satisfy Koch's postulates, showing that the CaMKII pathway is a core mechanism for promoting myocardial hypertrophy and heart failure. Multiple groups have now confirmed the following: (1) that CaMKII activity is increased in hypertrophied and failing myocardium from animal models and patients; (2) CaMKII overexpression causes myocardial hypertrophy and HF and (3) CaMKII inhibition (by drugs, inhibitory peptides and gene deletion) improves myocardial hypertrophy and HF. Patients with myocardial disease die in equal proportion from HF and arrhythmias, and a major therapeutic obstacle is that drugs designed to enhance myocardial contraction promote arrhythmias. In contrast, inhibiting the CaMKII pathway appears to reduce arrhythmias and improve myocardial responses to pathological stimuli. This brief paper will introduce the molecular physiology of CaMKII and discuss the impact of CaMKII on ion channels, Ca handling proteins and transcription in myocardium. This article is part of a special issue entitled {"}Key Signaling Molecules in Hypertrophy and Heart Failure{"}.",
keywords = "Arrhythmias, Calmodulin kinase II, Cell signaling, Heart failure, Hypertrophy, Oxidation",
author = "Anderson, {Mark E.} and Brown, {Joan Heller} and Bers, {Donald M}",
year = "2011",
month = "10",
doi = "10.1016/j.yjmcc.2011.01.012",
language = "English (US)",
volume = "51",
pages = "468--473",
journal = "Journal of Molecular and Cellular Cardiology",
issn = "0022-2828",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - CaMKII in myocardial hypertrophy and heart failure

AU - Anderson, Mark E.

AU - Brown, Joan Heller

AU - Bers, Donald M

PY - 2011/10

Y1 - 2011/10

N2 - Many signals have risen and fallen in the tide of investigation into mechanisms of myocardial hypertrophy and heart failure (HF). In our opinion, the multifunctional Ca and calmodulin-dependent protein kinase II (CaMKII) has emerged as a molecule to watch, in part because a solid body of accumulated data essentially satisfy Koch's postulates, showing that the CaMKII pathway is a core mechanism for promoting myocardial hypertrophy and heart failure. Multiple groups have now confirmed the following: (1) that CaMKII activity is increased in hypertrophied and failing myocardium from animal models and patients; (2) CaMKII overexpression causes myocardial hypertrophy and HF and (3) CaMKII inhibition (by drugs, inhibitory peptides and gene deletion) improves myocardial hypertrophy and HF. Patients with myocardial disease die in equal proportion from HF and arrhythmias, and a major therapeutic obstacle is that drugs designed to enhance myocardial contraction promote arrhythmias. In contrast, inhibiting the CaMKII pathway appears to reduce arrhythmias and improve myocardial responses to pathological stimuli. This brief paper will introduce the molecular physiology of CaMKII and discuss the impact of CaMKII on ion channels, Ca handling proteins and transcription in myocardium. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

AB - Many signals have risen and fallen in the tide of investigation into mechanisms of myocardial hypertrophy and heart failure (HF). In our opinion, the multifunctional Ca and calmodulin-dependent protein kinase II (CaMKII) has emerged as a molecule to watch, in part because a solid body of accumulated data essentially satisfy Koch's postulates, showing that the CaMKII pathway is a core mechanism for promoting myocardial hypertrophy and heart failure. Multiple groups have now confirmed the following: (1) that CaMKII activity is increased in hypertrophied and failing myocardium from animal models and patients; (2) CaMKII overexpression causes myocardial hypertrophy and HF and (3) CaMKII inhibition (by drugs, inhibitory peptides and gene deletion) improves myocardial hypertrophy and HF. Patients with myocardial disease die in equal proportion from HF and arrhythmias, and a major therapeutic obstacle is that drugs designed to enhance myocardial contraction promote arrhythmias. In contrast, inhibiting the CaMKII pathway appears to reduce arrhythmias and improve myocardial responses to pathological stimuli. This brief paper will introduce the molecular physiology of CaMKII and discuss the impact of CaMKII on ion channels, Ca handling proteins and transcription in myocardium. This article is part of a special issue entitled "Key Signaling Molecules in Hypertrophy and Heart Failure".

KW - Arrhythmias

KW - Calmodulin kinase II

KW - Cell signaling

KW - Heart failure

KW - Hypertrophy

KW - Oxidation

UR - http://www.scopus.com/inward/record.url?scp=79960044552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960044552&partnerID=8YFLogxK

U2 - 10.1016/j.yjmcc.2011.01.012

DO - 10.1016/j.yjmcc.2011.01.012

M3 - Article

C2 - 21276796

AN - SCOPUS:79960044552

VL - 51

SP - 468

EP - 473

JO - Journal of Molecular and Cellular Cardiology

JF - Journal of Molecular and Cellular Cardiology

SN - 0022-2828

IS - 4

ER -